The company offers a wide range of veterinary practices including companion animal, equine, and farm services, supported by over 2,300 veterinary surgeons and 3,200 nurses. CVS Group has completed the sale of its crematory business in May 2025 for an attractive 10x EBITDA multiple, with capital generated from the divestment providing additional resources for continued selective organic investment in the UK and expansion in Australia.
Cyborg Score Rationale
Market-leading position in UK veterinary services with 430+ practices and strategic diversification across companion, equine, and farm care. Recent crematorium divestment demonstrates disciplined capital allocation. However, currency and regulatory headwinds in the UK petcare market represent ongoing challenges.
Top Insights
Operates 430+ veterinary surgeries across UK and Australia with integrated diagnostics and online pharmacy capabilities
Recent May 2025 crematory divestment at attractive 10x EBITDA multiple redeploys capital toward higher-growth markets
Diversified revenue streams across companion animals, equine, farm, and referral services reduce concentration risk
Reported adjusted EPS of 80.1p down 3.2% due to increased depreciation and finance costs from debt increases
Named Competitors
Veterinary Services — UK-based veterinary practice aggregator with 600+ practices
Vets4Pets — Pet health and welfare services integrated with pet food portfolio
Veterinary Services — Consolidated UK veterinary practice operator
Recent Developments
(May 2025) Completed sale of crematory business at 10x EBITDA multiple
(December 2025) Reported adjusted EPS of 80.1p, down 3.2% YoY
(2025) Continued strategic investment in UK practices and Australian expansion
Open the full interactive CVS Group plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.